AK112 for advanced liver cancer (HCC)
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and willing to sign a consent form.
- Your liver cancer must be advanced and confirmed by biopsy or imaging.
- You should be able to do daily activities with little or no help (ECOG score 0 or 1).
- Your liver function must be good (Child-Pugh A).
- If you have already received treatment, it must have been no more than 2 previous types of systemic therapy, and you must not have had immunotherapy before.
- You must have at least one tumor that can be measured on scans and has not been treated with local therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if this combination can help control the cancer.
This trial is testing a new combination of drugs (an immunotherapy called AK104 plus a targeted therapy called lenvatinib) compared to lenvatinib alone, for people whose liver cancer has grown after they received the standard first-line treatment with atezolizumab and bevacizumab. The goal is to see if combining the two drugs can better control the cancer and help patients live longer.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.